These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25923950)

  • 21. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
    Arafa RK; Nour MS; El-Sayed NA
    Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
    Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
    Wu K; Ai J; Liu Q; Chen T; Zhao A; Peng X; Wang Y; Ji Y; Yao Q; Xu Y; Geng M; Zhang A
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6368-72. PubMed ID: 22985853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
    Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
    Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
    Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
    Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Akt Pathway Inhibitors.
    Uko NE; Güner OF; Matesic DF; Bowen JP
    Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.
    Strocchi E; Fornari F; Minguzzi M; Gramantieri L; Milazzo M; Rebuttini V; Breviglieri S; Camaggi CM; Locatelli E; Bolondi L; Comes-Franchini M
    Eur J Med Chem; 2012 Feb; 48():391-401. PubMed ID: 22227043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
    Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
    J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
    Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
    J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
    Determann R; Dreher J; Baumann K; Preu L; Jones PG; Totzke F; Schächtele C; Kubbutat MH; Kunick C
    Eur J Med Chem; 2012 Jul; 53():254-63. PubMed ID: 22560627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
    Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
    ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.
    Li JR; Li DD; Fang F; Du QR; Lin L; Sun J; Qian Y; Zhu HL
    Org Biomol Chem; 2013 Dec; 11(48):8375-86. PubMed ID: 24178241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.